JP2017536382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536382A5 JP2017536382A5 JP2017528775A JP2017528775A JP2017536382A5 JP 2017536382 A5 JP2017536382 A5 JP 2017536382A5 JP 2017528775 A JP2017528775 A JP 2017528775A JP 2017528775 A JP2017528775 A JP 2017528775A JP 2017536382 A5 JP2017536382 A5 JP 2017536382A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- salt
- species
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 27
- -1 4- (4- (4-(((3R Chemical class 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 206010017533 Fungal infection Diseases 0.000 claims description 12
- 208000024386 fungal infectious disease Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 241000228212 Aspergillus Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 6
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004413 flucytosine Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical group CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 claims description 2
- ZMYFCFLJBGAQRS-IRXDYDNUSA-N (2R,3S)-epoxiconazole Chemical compound C1=CC(F)=CC=C1[C@@]1(CN2N=CN=C2)[C@H](C=2C(=CC=CC=2)Cl)O1 ZMYFCFLJBGAQRS-IRXDYDNUSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 claims description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 108010020326 Caspofungin Proteins 0.000 claims description 2
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
- 108010049047 Echinocandins Proteins 0.000 claims description 2
- 239000005767 Epoxiconazole Substances 0.000 claims description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
- 229930195098 Hamycin Natural products 0.000 claims description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 2
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- 241000228143 Penicillium Species 0.000 claims description 2
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005822 Propiconazole Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- 241000235527 Rhizopus Species 0.000 claims description 2
- 240000005384 Rhizopus oryzae Species 0.000 claims description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 claims description 2
- AWGBZRVEGDNLDZ-UHFFFAOYSA-N Rimocidin Natural products C1C(C(C(O)C2)C(O)=O)OC2(O)CC(O)CCCC(=O)CC(O)C(CC)C(=O)OC(CCC)CC=CC=CC=CC=CC1OC1OC(C)C(O)C(N)C1O AWGBZRVEGDNLDZ-UHFFFAOYSA-N 0.000 claims description 2
- AWGBZRVEGDNLDZ-JCUCCFEFSA-N Rimocidine Chemical compound O([C@H]1/C=C/C=C/C=C/C=C/C[C@H](OC(=O)[C@@H](CC)[C@H](O)CC(=O)CCC[C@H](O)C[C@@]2(O)O[C@H]([C@@H]([C@@H](O)C2)C(O)=O)C1)CCC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O AWGBZRVEGDNLDZ-JCUCCFEFSA-N 0.000 claims description 2
- 241000223238 Trichophyton Species 0.000 claims description 2
- 241000222126 [Candida] glabrata Species 0.000 claims description 2
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 claims description 2
- 229950006373 abafungin Drugs 0.000 claims description 2
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 claims description 2
- 229950006816 albaconazole Drugs 0.000 claims description 2
- 229960003204 amorolfine Drugs 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- 229960002962 butenafine Drugs 0.000 claims description 2
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004348 candicidin Drugs 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 208000032343 candida glabrata infection Diseases 0.000 claims description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 2
- 229960003034 caspofungin Drugs 0.000 claims description 2
- 229960003749 ciclopirox Drugs 0.000 claims description 2
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 229960003937 efinaconazole Drugs 0.000 claims description 2
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 claims description 2
- 229960001274 fenticonazole Drugs 0.000 claims description 2
- 229960004884 fluconazole Drugs 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 229960002867 griseofulvin Drugs 0.000 claims description 2
- 229950006942 hamycin Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004849 isoconazole Drugs 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000570 luliconazole Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960003255 natamycin Drugs 0.000 claims description 2
- 235000010298 natamycin Nutrition 0.000 claims description 2
- 239000004311 natamycin Substances 0.000 claims description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- 229960004031 omoconazole Drugs 0.000 claims description 2
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229960001589 posaconazole Drugs 0.000 claims description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- STJLVHWMYQXCPB-UHFFFAOYSA-N propiconazole Chemical compound O1C(CCC)COC1(C=1C(=CC(Cl)=CC=1)Cl)CN1N=CN=C1 STJLVHWMYQXCPB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 229960005429 sertaconazole Drugs 0.000 claims description 2
- 229960002607 sulconazole Drugs 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- 229960000580 terconazole Drugs 0.000 claims description 2
- 229960004880 tolnaftate Drugs 0.000 claims description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002703 undecylenic acid Drugs 0.000 claims description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 2
- 229960004740 voriconazole Drugs 0.000 claims description 2
- 241000130764 Tinea Species 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 3
- 0 *C[C@@](C1)CO[C@@]1(C[n]1ncnc1)C1C(F)=CC(F)=CC1 Chemical compound *C[C@@](C1)CO[C@@]1(C[n]1ncnc1)C1C(F)=CC(F)=CC1 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196662.2 | 2014-12-05 | ||
| EP14196662 | 2014-12-05 | ||
| PCT/GB2015/053731 WO2016087878A1 (en) | 2014-12-05 | 2015-12-04 | Antimycotic compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536382A JP2017536382A (ja) | 2017-12-07 |
| JP2017536382A5 true JP2017536382A5 (cg-RX-API-DMAC7.html) | 2019-01-17 |
| JP6669751B2 JP6669751B2 (ja) | 2020-03-18 |
Family
ID=52006914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528789A Active JP6666345B2 (ja) | 2014-12-05 | 2015-12-04 | 抗真菌化合物 |
| JP2017528775A Active JP6669751B2 (ja) | 2014-12-05 | 2015-12-04 | 抗真菌化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528789A Active JP6666345B2 (ja) | 2014-12-05 | 2015-12-04 | 抗真菌化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (12) | US10106531B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3227277B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6666345B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102579848B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107001343B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015356795B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017008481B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2963625C (cg-RX-API-DMAC7.html) |
| DK (2) | DK3227277T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA033736B1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2790875T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE048905T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL251631B (cg-RX-API-DMAC7.html) |
| MX (1) | MX370412B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3227277T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3227277T (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201702835RA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016087880A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102579848B1 (ko) | 2014-12-05 | 2023-09-18 | 풀모사이드 리미티드 | 항진균 화합물 |
| WO2016097761A1 (en) | 2014-12-18 | 2016-06-23 | Pulmocide Limited | 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections |
| CN107635988B (zh) | 2015-05-21 | 2021-06-18 | 普尔莫赛德有限公司 | 抗真菌的苯甲酰胺类衍生物或其可药用盐 |
| WO2017093491A1 (en) * | 2015-12-04 | 2017-06-08 | Pulmocide Limited | Antimycotic triazole compound |
| RU2770033C2 (ru) * | 2016-11-28 | 2022-04-14 | Целликс Био Прайвет Лимитед | Композиции и способы лечения инфекционных заболеваний ротовой полости |
| WO2018115319A2 (en) | 2016-12-23 | 2018-06-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases |
| GB201917867D0 (en) * | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
| EP3858357A1 (en) * | 2020-01-28 | 2021-08-04 | Diaccurate | Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib |
| RU2770598C1 (ru) * | 2021-06-29 | 2022-04-18 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans |
| WO2025114603A1 (en) | 2023-11-30 | 2025-06-05 | Basilea Pharmaceutica International Ag, Allschwil | Pharmaceutical combinations for use in the treatment of fungal infections |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5533466A (en) * | 1978-07-14 | 1980-03-08 | Janssen Pharmaceutica Nv | Novel azole derivatives and their manufacture |
| CH655103A5 (de) * | 1983-03-11 | 1986-03-27 | Sandoz Ag | Azolderivate, verfahren zu ihrer herstellung und ihre verwendung. |
| CA1292472C (en) | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
| DE3609598A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
| JPH0717634B2 (ja) | 1987-11-20 | 1995-03-01 | シェリング・コーポレーション | トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体 |
| US5039678A (en) | 1989-03-23 | 1991-08-13 | Wake Forest University | Method of increasing cranial vessel proliferation by administering nimodipine |
| US5039676A (en) | 1990-05-11 | 1991-08-13 | Schering Corporation | Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof |
| US5403937A (en) * | 1993-04-30 | 1995-04-04 | Schering Corporation | Process for preparing intermediates for the synthesis of antifungal agents |
| JP2834889B2 (ja) | 1993-12-21 | 1998-12-14 | シェーリング コーポレイション | テトラヒドロフラン抗真菌剤 |
| US5714490A (en) | 1993-12-21 | 1998-02-03 | Schering Corporation | Tetrahydrofuran antifungals |
| US5486625A (en) | 1994-07-08 | 1996-01-23 | Schering Corporation | Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents |
| DE69628117T2 (de) | 1995-06-02 | 2004-04-01 | Schering Corp. | Antifungale tetrahydrofurane |
| EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| KR100607742B1 (ko) | 2001-04-03 | 2006-08-01 | 쉐링 코포레이션 | 안정한 액상 현탁제, 및 이를 함유하는, 생체 이용율이 증진된 항진균성 조성물 |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| EP3263568B1 (en) * | 2011-07-18 | 2021-08-25 | Merck Patent GmbH | Benzamides |
| WO2013036866A1 (en) | 2011-09-07 | 2013-03-14 | The Johns Hopkins University | Itraconazole analogs and use thereof |
| KR102579848B1 (ko) | 2014-12-05 | 2023-09-18 | 풀모사이드 리미티드 | 항진균 화합물 |
| GB201917867D0 (en) | 2019-12-06 | 2020-01-22 | Pulmocide Ltd | Polymorphs |
-
2015
- 2015-12-04 KR KR1020177013730A patent/KR102579848B1/ko active Active
- 2015-12-04 CN CN201580066092.6A patent/CN107001343B/zh active Active
- 2015-12-04 JP JP2017528789A patent/JP6666345B2/ja active Active
- 2015-12-04 EA EA201791174A patent/EA033736B1/ru not_active IP Right Cessation
- 2015-12-04 ES ES15808770T patent/ES2790875T3/es active Active
- 2015-12-04 EP EP15808770.0A patent/EP3227277B1/en active Active
- 2015-12-04 HU HUE15808770A patent/HUE048905T2/hu unknown
- 2015-12-04 CA CA2963625A patent/CA2963625C/en active Active
- 2015-12-04 DK DK15808770.0T patent/DK3227277T3/da active
- 2015-12-04 JP JP2017528775A patent/JP6669751B2/ja active Active
- 2015-12-04 AU AU2015356795A patent/AU2015356795B2/en active Active
- 2015-12-04 US US15/524,505 patent/US10106531B2/en active Active
- 2015-12-04 ES ES15817507T patent/ES2786374T3/es active Active
- 2015-12-04 WO PCT/GB2015/053733 patent/WO2016087880A1/en not_active Ceased
- 2015-12-04 MX MX2017007188A patent/MX370412B/es active IP Right Grant
- 2015-12-04 PL PL15808770T patent/PL3227277T3/pl unknown
- 2015-12-04 PT PT158087700T patent/PT3227277T/pt unknown
- 2015-12-04 SG SG11201702835RA patent/SG11201702835RA/en unknown
- 2015-12-04 HU HUE15817507A patent/HUE048685T2/hu unknown
- 2015-12-04 CN CN202011308132.2A patent/CN112375073B/zh active Active
- 2015-12-04 BR BR112017008481-3A patent/BR112017008481B1/pt active IP Right Grant
- 2015-12-04 EP EP15817507.5A patent/EP3227278B1/en active Active
- 2015-12-04 WO PCT/GB2015/053731 patent/WO2016087878A1/en not_active Ceased
- 2015-12-04 DK DK15817507.5T patent/DK3227278T3/da active
-
2016
- 2016-10-20 US US15/298,431 patent/US10093659B2/en active Active
-
2017
- 2017-04-06 IL IL251631A patent/IL251631B/en active IP Right Grant
-
2018
- 2018-09-12 US US16/129,322 patent/US10487073B2/en active Active
- 2018-09-24 US US16/139,591 patent/US10344022B2/en active Active
-
2019
- 2019-05-24 US US16/422,062 patent/US10450304B2/en active Active
- 2019-09-12 US US16/569,128 patent/US10662179B2/en active Active
- 2019-10-04 US US16/593,444 patent/US10800762B2/en active Active
-
2020
- 2020-04-15 US US16/849,476 patent/US10858345B2/en active Active
- 2020-09-04 US US17/012,685 patent/US11008307B2/en active Active
- 2020-11-04 US US17/089,441 patent/US11661415B2/en active Active
-
2021
- 2021-04-14 US US17/230,009 patent/US20210238169A1/en not_active Abandoned
-
2023
- 2023-04-18 US US18/302,557 patent/US12269814B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536382A5 (cg-RX-API-DMAC7.html) | ||
| JP2017536385A5 (cg-RX-API-DMAC7.html) | ||
| JP2017536371A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500779A5 (cg-RX-API-DMAC7.html) | ||
| JP2017519036A5 (cg-RX-API-DMAC7.html) | ||
| RU2496774C2 (ru) | Гетероциклические ингибиторы аспартильной протеазы | |
| CN107001343B (zh) | 抗真菌的化合物 | |
| US6407129B1 (en) | Azole compounds, their production and their use | |
| JP2006505576A (ja) | アリールアミジン誘導体を含む抗真菌薬 | |
| JP2011508774A5 (cg-RX-API-DMAC7.html) | ||
| AU2006339842A1 (en) | Pharmaceutical composition for external use | |
| FI4069690T3 (fi) | Triatsolisienilääkeyhdiste pc945:n polymorfeja | |
| NZ613167A (en) | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds | |
| JP2013545819A5 (cg-RX-API-DMAC7.html) | ||
| JP2007534764A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501879A5 (cg-RX-API-DMAC7.html) | ||
| FI120079B (fi) | Antifungaalisia koostumuksia, jotka sisältävät terbinafiinia ja atsoli-14(alfa)-metyylidemetyylaasi-estäjää | |
| JP2021503001A5 (cg-RX-API-DMAC7.html) | ||
| RU2006141653A (ru) | Доставка противогрибковых лекарственных средств | |
| PH12017501831A1 (en) | Pharmaceutical compositions for oral administration | |
| US20210260196A1 (en) | Formulation comprising active pharmaceutical ingredient | |
| CN1535149B (zh) | 噻唑基酰胺类化合物的局部应用 | |
| CN105745193B (zh) | 抗真菌氧代二氢吡啶碳酰肼衍生物 | |
| JP2018520104A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021111142A5 (cg-RX-API-DMAC7.html) |